My watch list

Vernalis

Vernalis plc (LSE:VER.L Nasdaq:VNLS)
	Public
Founded	2003 from merger
Headquarters	Winnersh, United Kingdom
Key people	CEO Robert Mansfield, 1992-2003 Simon Sturge, 2003- Chair George Kennedy, 2000-2003 Peter Fellner, 2003-
Industry	Biotechnology
Products	Frovatriptan, Apokyn
Employees	200
Website	Vernalis

Vernalis Plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.^[1] The merger allowed British Biotech to ditch its historic but tarnished name.^[2]

Additional recommended knowledge

How to ensure accurate weighing results every day?

Weighing the right way

What is the Correct Way to Check Repeatability in Balances?

The company has marketed two drug products; Frovatriptan,,^[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.^[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono.

References

^ Vernalis agrees £91m merger plan with British Biotech. Advances in Life Science. ALS (2003). Retrieved on 2003-07-03.
^ Fifth Report. Select Committee on Science and Technology. House of Commons (1998). Retrieved on 2007-11-28.
^ Patient Information Sheet -- Frovatriptan succinate (marketed as Frova). Food and Drug Administration (07/2006). Retrieved on 2007-11-28.
^ Apokyn. FDA (2004). Retrieved on 2004-07-29.